CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Frequently asked questions
What sector does CervoMed Inc. (CRVO) operate in?
CervoMed Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is CervoMed Inc. (CRVO) current stock price?
As of the latest data, CervoMed Inc. stock price is $2.71, with a previous close of $2.73. CervoMed Inc. lost -$0.02 in the last trading session, representing a -0.73% loss.
What is CervoMed Inc. (CRVO) current market capitalization?
CervoMed Inc. market cap is approximately 36.66 million.
What is CervoMed Inc. (CRVO) Earnings Per Share (EPS)?
The trailing EPS is -$3.28, and the forward EPS is -$2.51.
What is CervoMed Inc. (CRVO) EBITDA?
CervoMed Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -6.57 million.
Does CervoMed Inc. (CRVO) pay dividends?
No. CervoMed Inc. does not pay a dividend.
What is CervoMed Inc. (CRVO) beta (volatility) score?
CervoMed Inc. has a beta of -4.310, indicating lower volatility than the overall market.
